According to the complaint, the network was processing a huge volume of reimbursement claims for Gilead's HIV pre-exposure prophylaxis (PrEP) medicines Truvada (emtricitabine/tenofovir disoproxil ...

Gilead Sciences has bolstered its position as a leader in the HIV research space by purchasing an investigational HIV vaccine from Spanish biotech Aelix Therapeutics. The companies first linked up ...

[1] Tenofovir disoproxil fumarate (Viread, Gilead Sciences, Inc.) is a new addition to the antiretroviral armamentarium. It is an ester-derived prodrug that is converted in vivo by serum and ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...

This case challenges the mandated ... Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi. Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

The combination of tenofovir, didanosine, and lamivudine is not recommended when considering a new treatment regimen for therapy-naive or treatment-experienced patients with HIV infection.